BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

(2018) Clare E. Weeden et al.   ONCOGENE

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

(2018) Georgia Greaves et al.   CELL DEATH AND DIFFERENTIATION

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies

(2018) Sean Caenepeel et al.   Cancer Discovery

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

(2017) Bibhusal Thapa et al.   Journal of Thoracic Oncology

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

(2017) T-C Teh et al.   LEUKEMIA

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

(2016) J.-N. Gong et al.   BLOOD

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM

(2016) Leona Rohrbeck et al.   CELL DEATH AND DIFFERENTIATION

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Role of the pro-survival molecule Bfl-1 in melanoma

(2015) C.K. Hind et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

(2015) Y. Xiao et al.   MOLECULAR CANCER THERAPEUTICS

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

(2015) Brandon J. Aubrey et al.   Cell Reports

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids

(2015) Kimberley A. Beaumont et al.   Jove-Journal of Visualized Experiments

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

(2014) M N Serasinghe et al.   ONCOGENE

Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells

(2014) Arnim Weber et al.   Translational Oncology

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel

(2013) Andreas Behren et al.   Pigment Cell & Melanoma Research

BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

(2013) Rizwan Haq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

(2012) D. Wroblewski et al.   CARCINOGENESIS

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1

(2012) Daniela Senft et al.   PLoS One

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

(2011) K. M. Lucas et al.   CLINICAL CANCER RESEARCH

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization

(2011) Haiming Dai et al.   JOURNAL OF CELL BIOLOGY

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-737 synergizes with Bortezomib to kill melanoma cells

(2011) S. N. Reuland et al.   Biology Open

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

(2010) W J Placzek et al.   Cell Death & Disease

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway

(2009) Angela M. Keuling et al.   PLoS One

Melanocytes: From Morphology to Application

(2009) A. Santiago-Walker et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

BH3 Mimetic ABT-737 and a Proteasome Inhibitor Synergistically Kill Melanomas through Noxa-Dependent Apoptosis

(2008) Leslie A. Miller et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax

(2008) J. I. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA